NervGen Pharma Corp. (NASDAQ:NGEN) — Market Cap & Net Worth
Market Cap & Net Worth: NervGen Pharma Corp. (NGEN)
NervGen Pharma Corp. (NASDAQ:NGEN) has a market capitalization of $178.24 Million ($178.24 Million) as of July 24, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16973 globally and #3973 in its home market, demonstrating a -0.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NervGen Pharma Corp.'s stock price $1.68 by its total outstanding shares 106412633 (106.41 Million). Review NervGen Pharma Corp. balance sheet liabilities to assess the company's total debt and financial obligations.
NervGen Pharma Corp. Market Cap History: 2026 to 2026
NervGen Pharma Corp.'s market capitalization history from 2026 to 2026. Data shows growth from $178.24 Million to $178.24 Million (0.00% CAGR).
NervGen Pharma Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NervGen Pharma Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NGEN by Market Capitalization
Companies near NervGen Pharma Corp. in the global market cap rankings as of July 24, 2026.
Key companies related to NervGen Pharma Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #427 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $473.09 |
| #427 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $651.91 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €797.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €243.00 |
NervGen Pharma Corp. Historical Marketcap From 2026 to 2026
Between 2026 and today, NervGen Pharma Corp.'s market cap moved from $178.24 Million to $ 178.24 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $178.24 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 24th, 2026 the market cap of NervGen Pharma Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $178.24 Million USD |
| MoneyControl | $178.24 Million USD |
| MarketWatch | $178.24 Million USD |
| marketcap.company | $178.24 Million USD |
| Reuters | $178.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's… Read more